コンテンツへスキップ
Merck
  • Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.

Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.

Journal of medicinal chemistry (2009-12-19)
Jiangnan Peng, Sucheta Kudrimoti, Sivaprakasam Prasanna, Srinivas Odde, Robert J Doerksen, Hari K Pennaka, Yeun-Mun Choo, Karumanchi V Rao, Babu L Tekwani, Vamsi Madgula, Shabana I Khan, Bin Wang, Alejandro M S Mayer, Melissa R Jacob, Lan Chun Tu, Jürg Gertsch, Mark T Hamann
要旨

Structure-activity relationship studies were carried out by chemical modification of manzamine A (1), 8-hydroxymanzamine A (2), manzamine F (14), and ircinal isolated from the sponge Acanthostrongylophora. The derived analogues were evaluated for antimalarial, antimicrobial, and antineuroinflammatory activities. Several modified products exhibited potent and improved in vitro antineuroinflammatory, antimicrobial, and antimalarial activity. 1 showed improved activity against malaria compared to chloroquine in both multi- and single-dose in vivo experiments. The significant antimalarial potential was revealed by a 100% cure rate of malaria in mice with one administration of 100 mg/kg of 1. The potent antineuroinflammatory activity of the manzamines will provide great benefit for the prevention and treatment of cerebral infections (e.g., Cryptococcus and Plasmodium). In addition, 1 was shown to permeate across the blood-brain barrier (BBB) in an in vitro model using a MDR-MDCK monolayer. Docking studies support that 2 binds to the ATP-noncompetitive pocket of glycogen synthesis kinase-3beta (GSK-3beta), which is a putative target of manzamines. On the basis of the results presented here, it will be possible to initiate rational drug design efforts around this natural product scaffold for the treatment of several different diseases.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リファンピシン, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
カフェイン, anhydrous, 99%, FCC, FG
Sigma-Aldrich
リファンピシン, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
キニーネ, 90%
Sigma-Aldrich
5-メトキシトリプタミン, 97%
Sigma-Aldrich
キニーネ, suitable for fluorescence, anhydrous, ≥98.0% (dried material, NT)
Sigma-Aldrich
カフェイン, powder, ReagentPlus®
Sigma-Aldrich
シプロフロキサシン, ≥98% (HPLC)
Sigma-Aldrich
カフェイン, Sigma Reference Standard, vial of 250 mg
Supelco
融点スタンダード235~237°C, analytical standard
5-メトキシトリプタミン, British Pharmacopoeia (BP) Reference Standard
Supelco
カフェイン 溶液, analytical standard, 1.0 mg/mL in methanol
Sigma-Aldrich
カフェイン, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
カフェイン, meets USP testing specifications, anhydrous
Supelco
Mettler-Toledo®キャリブレーション用物質ME 18872、カフェイン, traceable to primary standards (LGC)
Sigma-Aldrich
カフェイン, BioXtra
Supelco
シプロフロキサシン, VETRANAL®, analytical standard
Supelco
5-メトキシトリプタミン, Pharmaceutical Secondary Standard; Certified Reference Material